Teva Fears Profit Plunge as Patent on Multiple Sclerosis Drug Runs Out

After a months-long legal battle, U.S. Supreme Court's decision to lift patent on Teva's multiple sclerosis drug opens the door for new competition.

Send in e-mailSend in e-mail

Comments